Literature DB >> 8608351

A protective role for testosterone in adjuvant-induced arthritis.

M S Harbuz1, Z Perveen-Gill, S L Lightman, D S Jessop.   

Abstract

We have investigated the role of the gonadal steroids testosterone (T) and progesterone in modulating: (1) the onset and severity of adjuvant-induced arthritis (AA), (2) the response of the hypothalamo-pituitary-adrenal (HPA) axis, and (3) the levels of plasma prolactin and anterior pituitary prolactin messenger ribonucleic acid (mRNA) in the rat. Male rats were castrated (CSX) and received either no T, low T or high T delivered using silastic implants. In a second study experimental groups comprised CSX/AA, CSX/AA + progesterone or CSX/AA + progesterone + T. The time of onset was sooner and the severity of AA was greater in CSX rats. Inflammation was prevented by T replacement. Endogenous plasma T levels were decreased in AA rats. In control animals with AA there was an increase in pro-opiomelanocortin (POMC) mRNA in the anterior pituitary and of plasma corticosterone, and a decrease in corticotrophin-releasing factor (CRF) mRNA. These changes in the HPA axis of AA and CSX/AA rats were reversed by T replacement. These data suggest that T has an important protective effect on the progress and severity of AA. This was reflected by a reversal of the neuroendocrine changes of the HPA axis. Progesterone treatment alone had no effect on the severity of the disease. Prolactin mRNA in the anterior pituitary was decreased in the CSX and in the CSX/AA group but was not altered by AA. Plasma prolactin was raised in AA but T replacement did not reduce these elevated levels despite the absence of disease. Thus, prolactin provides a poor indicator of inflammation, suggesting that it may not be a potent pro-inflammatory compound in AA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8608351     DOI: 10.1093/rheumatology/34.12.1117

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  19 in total

1.  Androgens suppress antigen-specific T cell responses and IFN-γ production during intracranial LCMV infection.

Authors:  Adora A Lin; Sara E Wojciechowski; David A Hildeman
Journal:  J Neuroimmunol       Date:  2010-09-14       Impact factor: 3.478

Review 2.  Estrogen and testosterone therapies in multiple sclerosis.

Authors:  Stefan M Gold; Rhonda R Voskuhl
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

Review 3.  Relations between steroid hormones and cytokines in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  M Cutolo; A Sulli; B Villaggio; B Seriolo; S Accardo
Journal:  Ann Rheum Dis       Date:  1998-10       Impact factor: 19.103

4.  Sex steroid regulation of the inflammatory response: sympathoadrenal dependence in the female rat.

Authors:  P G Green; S R Dahlqvist; W M Isenberg; H J Strausbaugh; F J Miao; J D Levine
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

5.  Modulation of temporomandibular joint nociception and inflammation in male rats after administering a physiological concentration of 17β-oestradiol.

Authors:  P R Kramer; L L Bellinger
Journal:  Eur J Pain       Date:  2012-06-19       Impact factor: 3.931

6.  Anabolic-androgenic steroid effects on nociception and morphine antinociception in male rats.

Authors:  K T Tsutsui; R I Wood; R M Craft
Journal:  Pharmacol Biochem Behav       Date:  2011-05-05       Impact factor: 3.533

Review 7.  Gender issues and multiple sclerosis.

Authors:  Rhonda R Voskuhl
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

8.  Decreased opioid analgesia in weanling rats exposed to endothelin-1 during infancy.

Authors:  Alvin D McKelvy; Sarah M Sweitzer
Journal:  Neurosci Lett       Date:  2009-09-27       Impact factor: 3.046

9.  Gonadotropin treatment restores in vitro interleukin-1beta and tumour necrosis factor-alpha production by stimulated peripheral blood mononuclear cells from patients with idiopathic hypogonadotropic hypogonadism.

Authors:  U Musabak; E Bolu; M Ozata; C Oktenli; A Sengul; A Inal; Z Yesilova; G Kilciler; I C Ozdemir; I H Kocar
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

10.  A case of hypogonadotropic hypogonadism caused by opioid treatment for nonmalignant chronic pain.

Authors:  Yukiko Tabuchi; Tetsuyuki Yasuda; Hideaki Kaneto; Tetsuhiro Kitamura; Junji Kozawa; Michio Otsuki; Akihisa Imagawa; Aya Nakae; Youichi Matsuda; Hironobu Uematsu; Takashi Mashimo; Masahiko Shibata; Iichiro Shimomura
Journal:  Case Rep Med       Date:  2012-12-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.